308 related articles for article (PubMed ID: 17155984)
1. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
[TBL] [Abstract][Full Text] [Related]
2. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
3. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
5. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.
Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB
J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
11. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
13. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
[TBL] [Abstract][Full Text] [Related]
14. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
[TBL] [Abstract][Full Text] [Related]
15. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
16. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
[TBL] [Abstract][Full Text] [Related]
17. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
18. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.
Furihata M; Inoue K; Ohtsuki Y; Hashimoto H; Terao N; Fujita Y
Cancer Res; 1993 Oct; 53(20):4823-7. PubMed ID: 8402668
[TBL] [Abstract][Full Text] [Related]
19. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.
Youssef R; Kapur P; Shariat SF; Arendt T; Kabbani W; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
BJU Int; 2012 Oct; 110(7):961-6. PubMed ID: 22372762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]